CD163 might not be the most exciting name in the world, but behind it lies one of the body's most important defense receptors ...
Carisma Therapeutics is developing a unique, differentiated immuno-oncology (IO) treatment for solid tumors based on chimeric antigen receptor macrophages (CAR-M). Current IO treatments have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback